^(18)FDG PET／CT标准摄取值与非小细胞肺癌临床分期关系的研究

Correlation between standard uptake value of ^(18)FDG PET/CT and clinical staging of non-small cell lung cancer

目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者治疗前的18氟脱氧葡萄糖(18F-deoxyglucose,18 FDG) PET／CT标准摄取值(standard uptake value, SUV)与临床分期、原发肿瘤大小及病理学类型的关系。方法:对75例治疗前的NSCLC患者接受18FDG PET／CT检查获得最高SUV (SUVmax)。分析SUVmax与临床分期、原发肿瘤分期、肿瘤大小和病理学类型的关系,并研究SUV在四者组内差异是否有统计学意义。结果:SUVmax与临床分期和原发肿瘤大小均呈正相关(r=0．279,P=0．014;r= 0．645,P=0．001),与肿瘤病理学类型无关(r=-0．077,P=0．507);SUV在两组不同大小肿瘤组(≤3．0 cm和>3．0 cm)间差异有统计学意义,t=-0．647,P=0．015,在各个临床分期组(ⅠA～ⅡB、ⅢA和m B～Ⅳ)间差异有统计学意义,F=3．807,P=0．027,在4个原发肿瘤分期组(T1、T2、T3和T4)间差异有统计学意义,F=8．025,P=0．022,而在不同病理学类型组(鳞癌、腺癌和腺鳞癌)间差异无统计学意义,F=1．911,P=0．155。结论:18FDG PET／CT SUV随肿瘤大小和病期的增加呈升高趋势,可以作为评价NSCLC临床分期的辅助手段,但不能为无法取得病理学诊断的患者提供帮助。

OBJECTIVE： To investigate the correlation between standard uptake value （SUV） of ^18F-fluorodeoxyglucose Positron Emission Tomography （^18FDG PET/CT ） and the clinical staging, primary tumor size, pathological type of non-small cell lung cancer （NSCLC） patients who received the examination of ^18FDG PET/CT before the treatment. METHODS： 75 patients with biopsy-proven NSCLC were included in the protocol. All cases had whole body ^18FDG PET/CT scans prior to the treatment. Maximal SUVs （SUVmax） which were obtained by selecting a small region of interest （ROI） were used in the analysis. RESULTS： Clinical staging was positively related to SUV, r = 0. 279, P = 0. 014; SUVs were obviously different among the three clinical staging groups by single factor analysis of variance, F= 3. 807, P = 0. 027. The correlation between SUV and the two groups standed for primary tumor size were observed, r=0. 645, P=0. 001. Independent t-test showed that there were significant differences in SUV between the two groups, t= -0. 647, P= 0. 015. Single factor analysis of variance showed that SUVs were different among four T staging groups, F=8. 025, P=0. 022. However, the correlation between SUV and pathological type had no statistical difference, r=-0. 077, P=0. 507, and single factor analysis of variance demonstrated adverse outcome among the pathological type groups, F = 1. 911, P = 0. 155. CONCLUSIONS： Both primary tumor size and clinical staging of NSCLC can be evaluated by ^18FDG PET/CT SUV, but pathological type of NSCLC is not related to SUV.